Tennessee Senate Bill SB2080

Tennessee 2023-2024 Regular Session

• Introduced: 1/29/24
• Chaptered: 3/26/24
• Passed: 3/26/24

Caption

AN ACT to amend Tennessee Code Annotated, Section 53-11-311 and Section 63-1-164, relative to deleting references to repealed federal law.

Impact

The implications of SB 2080 are significant for both healthcare providers and patients. By eliminating outdated references to federal law, this bill aims to simplify the prescribing process for buprenorphine, which can increase access for patients struggling with opioid addiction. It also aims to ensure that physicians can prescribe the medication without unnecessary bureaucratic hurdles, thereby facilitating a more responsive and effective treatment environment for those in need.

Summary

Senate Bill 2080 seeks to amend Tennessee's Code Annotated by removing references to certain repealed federal laws related to the prescription of buprenorphine, a medication used in opioid addiction treatment. The bill explicitly states that a product containing buprenorphine can only be prescribed in accordance with guidelines recognized by the FDA. This bill aims to streamline and clarify the legal framework surrounding the prescription of buprenorphine, ensuring it aligns with current medical practices and federal regulations.

Sentiment

The sentiment towards SB 2080 appears to be largely supportive, especially among healthcare providers who see the bill as a means to improve access to essential treatments for opioid addiction. Advocates argue that by modernizing the legal framework, it promotes a more effective response to the ongoing opioid crisis. However, there may be concerns among some legislators about ensuring that the removal of federal references does not compromise the standards of care or patient safety guidelines.

Contention

One notable point of contention surrounding SB 2080 could be the extent to which it relies on state versus federal guidelines for medical prescriptions. There may be debate about whether the bill sufficiently safeguards the standards necessary for prescribing buprenorphine, particularly regarding accountability and oversight mechanisms that are traditionally governed by federal regulations. Ensuring that these changes do not weaken protections or access for patients with legitimate needs will be critical as the bill progresses.